Related Experiment Video

Updated: Jun 11, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis

J C Goebel1, M Roesel, C Heinz

  • 1Department of Ophthalmology, Uveitis Center at St. Franziskus-Hospital, Muenster, Germany.

The British Journal of Ophthalmology
|June 30, 2010
PubMed

Insights

Azathioprine effectively treats uveitis in juvenile idiopathic arthritis (JIA), achieving inactivity in most patients. This immunosuppressive therapy can reduce steroid dependence and is a valuable option for JIA-associated uveitis.

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Background:

  • Juvenile idiopathic arthritis (JIA) frequently causes chronic anterior uveitis.
  • Uveitis in JIA can lead to vision impairment and requires effective immunosuppressive management.

Purpose of the Study:

  • To evaluate azathioprine's efficacy as monotherapy or in combination for treating JIA-associated uveitis.
  • To assess azathioprine's role in reducing corticosteroid and other immunosuppressive drug dosages.

Main Methods:

  • Retrospective multicentre study of 41 children with JIA and chronic anterior uveitis.
  • Azathioprine was administered to patients with active uveitis despite existing treatments.
  • Primary endpoint: uveitis inactivity; Secondary endpoints: steroid dose sparing and immunosuppression levels.

Main Results:

  • Uveitis inactivity achieved in 76.5% with azathioprine monotherapy and 56.6% with combination therapy at 1 year.
  • Long-term inactivity (mean 26 months) observed in 61.5% (monotherapy) and 66.7% (combination).
  • Significant reduction in systemic/topical steroid dosages and immunosuppression achieved in multiple patients; 7.3% discontinued due to side effects.

Conclusions:

  • Azathioprine is a viable option in the treatment ladder for JIA-associated uveitis.
  • Adding azathioprine may benefit patients unresponsive to methotrexate.
  • Azathioprine demonstrates therapeutic value in managing JIA-uveitis, potentially reducing steroid burden.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...